Yizhou Yu addresses the lack of personalised treatments for Alzheimer’s disease by investigating genetic, cellular, and population-level aspects. He combined laboratory techniques and machine learning to identify a novel pathway, leading to the development of probiotic bacteria that delay neuron death in animal models, offering a potential solution for Alzheimer’s disease.
Yizhou Yu is a PhD student at the University of Cambridge. His research investigates the mechanisms of Alzheimer’s disease by using cell and animal models in combination with human genetic, microbiome, biochemical, behavioural, and brain imaging data. He then leverages these biological insights to develop personalised therapies against Alzheimer’s disease and inform drug safety.